Alex Nivorozhkin, PhD

Alex has a broad synthetic and physical organic chemistry background, with specific training and expertise in enzymatic processes. He transitioned from academic research into the pharmaceutical industry, first as a medicinal chemist and subsequently as a research manager with a broad range of responsibilities. He has been a key contributor to multiple industrial pharma projects, from early discovery and development to advanced preclinical development and launch of Phase 1 and 2 clinical trials. As part of these activities, he oversaw the major section of the IND filings and related CMC sections. Additionally, he was an investigator and PI on multiple SBIR grants to develop new drugs and drug formulations in oncology, cardiovascular, infectious disease, and other conditions. He successfully administered multiple industrial programs, including strategy, staffing, budget, and timelines, and collaborated with other researchers. In later years, he was deeply involved in drug formulation and drug delivery aspects of pharmaceutical development, including natural products such as proteins (HSP70), cannabinoids, phytocannabinoids, and psychedelics. These projects stem from his own inventions that profoundly affect the pharmacology of the known drug scaffold via selective chemical modifications and specific drug formulation approaches.